SANA Sana Biotechnology

Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category

Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category

SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it has been named the top place to work on the small employer list.

“We are honored to be on the BioSpace 2023 Best Places to Work list,” said Steve Harr, Sana’s President and Chief Executive Officer. “Since our founding, we have prioritized the creation of an environment where candor, inclusivity, and psychological safety co-exist. We do so to foster innovation, truth-seeking, and growth for our team, ingredients we deem essential to the development of medicines that improve patients’ lives. The BioSpace recognition validates our innovative work culture as well as the hard work, resilience, and commitment of Sana employees.”

The 2023 BioSpace Best Places to Work list includes 60 U.S. operating employers that are recognized as the most sought-after in the industry by the life sciences community. With over 2,000 life sciences professionals, respondents identified their top three most desirable biopharma companies, segmented by large (more than 1,000+ employees) and small (less than 1,000 employees) companies. Respondents were also asked to rate their top choice organizations on attributes including: compensation, innovation, career growth opportunities, leadership, culture, diversity, equity and inclusion, reputation, and flexibility and remote work.

About Sana Biotechnology

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit .

Investor Relations & Media:

Nicole Keith





EN
14/11/2022

Underlying

SANASana Biotechnology

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sana Biotechnology

 PRESS RELEASE
Free
SANA Sana Biotechnol...

Sana Biotechnology Reports Second Quarter 2025 Financial Results and B...

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C-peptide New England Journal of Medicine published positive 12-week clinical results of the type 1 diabetes study Recent FDA INTERACT meeting increases confidence in moving forward with GMP master cell bank for SC451 and in filing SC451 Investigational N...

August 11, 2025 1 EN
 PRESS RELEASE
Free
SANA Sana Biotechnol...

Sana Biotechnology Announces Pricing of Public Offering

Sana Biotechnology Announces Pricing of Public Offering SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten public offering of 20,895,522 shares of its common stock at a price to the public of $3.35 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,492,537 shares of common stock at a price to the public of $3.3499 per pre-funded warrant, which represents the per share publ...

August 7, 2025 1 EN
 PRESS RELEASE
Free
SANA Sana Biotechnol...

Sana Biotechnology Announces Proposed Public Offering of Common Stock ...

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additiona...

August 6, 2025 1 EN
 PRESS RELEASE
Free
SANA Sana Biotechnol...

Sana Biotechnology Announces Publication in New England Journal of Med...

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes Data Demonstrate that Sana’s Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to Genetically Modify and Transplant Pancreatic Islet Cells Without Immunosuppression and Overcome Both Allogeneic and Autoimmune Rejection ...

August 4, 2025 1 EN
 PRESS RELEASE
Free
SANA Sana Biotechnol...

Sana Biotechnology Announces Positive Six-Month Clinical Results from ...

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate that Sana’s Transplanted Pancreatic Islet Cells Modified with its Hypoimmune (HIP) Technology are Safe and Well-tolerated, Survive, Evade Detection by the Immune System, and Continue to Produce Insulin in the Patient Function and Persistence of ...

June 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch